BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ScinoPharm Reports Final FY2009 Results All-Time Highs for Revenue and Operating Profit


3/25/2010 9:23:38 AM

TAIWAN, March 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008. The company posted after-tax profit of NT $1.041 billion, an increase of approximately 19.37% over 2008.

The increase was driven by the continued strong sales of its anti-cancer and other therapeutic treatments products, as well as increased demands from Europe, Japan, Korea and India. This marks the tenth consecutive year of double digit revenue growth.

"We delivered solid performance in 2009 and look forward to growing our top and bottom line in 2010," said Dr. Jo Shen, President and CEO of ScinoPharm. "Our performance is directly attributed to our core strategy of focusing on high value and high technological barrier products, which will further ScinoPharm's market leadership position in generic APIs," Dr. Shen added.

2010 Outlook

ScinoPharm has several new API products for generic drugs scheduled for commercialization in 2010, including products for breast cancer, prostate cancer, and ovarian cancer. In addition, two New Chemical Entity (NCE) projects are expected to get approval from FDA for commercial launch.

ScinoPharm has also accelerated its pace by developing cell lines and lab processes for seven biosimilars. Among them are monoclonal antibodies used in the treatment of cancer and rheumatoid arthritis. ScinoPharm also continues to expand with the construction of a new production facility and a new R&D site in Changshu, Jiangsu Province, scheduled to be completed in 2011.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. Combining cost-effective resources and productivity of Asia along with extensive regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector. For more information please visit http://www.scinopharm.com .

CONTACT: Sabrian Wu of ScinoPharm Taiwan, +886-6-505-2869, or +886-920-
056-385, or sabrina.wu@scinopharm.com.tw

Web site: http://www.scinopharm.com//



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES